MARK DURDEN: Open Payments
NPI 1518087907 · MACON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,668 in 58 payments from 12 companies in 2025. Trend: 2023 $693 · 2024 $1,604 · 2025 $1,668
Food & beverage: $1,565Education: $103
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 21 | $567 |
| Janssen Pharmaceuticals, Inc | 12 | $398 |
| Neurocrine BioSciences, Inc. | 2 | $239 |
| Vanda Pharmaceuticals Inc. | 8 | $176 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $93 |
| Alkermes, Inc. | 4 | $62 |
| E.R. Squibb & Sons, L.L.C. | 2 | $49 |
| Lundbeck LLC | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
Products named: INVEGA SUSTENNA, AUSTEDO XR, INGREZZA, FANAPT, UZEDY, CAPLYTA, ARISTADA, COBENFY.
Industry payments across GA — which companies pay providers there.
